Osimertinib

1421373-65-0

C28H33N7O2

DMSO : 100 mg/mL (200.16 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Osimertinib (AZD-9291) is an irreversible and mutant selective EGFR inhibitor with IC₅₀s of 12 and 1 nM against EGFR^L858R and EGFR^L858R/T790M, respectively. IC50 & Target: IC50: 1 nM (EGFR^L858R/T790M), 12 nM (EGFR^L858R)^[1] In Vitro: Osimertinib (AZD-9291) shows similar potency to early generation tyrosine kinase inhibitor (TKIs) in inhibiting EGFR phosphorylation in EGFR cells harboring sensitising EGFR mutants including PC-9 (ex19del), H3255 (L858R) and H1650 (ex19del), with mean IC₅₀ values ranging from 13 to 54 nM for AZD-9291. Osimertinib (AZD-9291) also potently inhibits phosphorylation of EGFR in T790M mutant cell lines (H1975 (L858R/T790M), PC-9VanR (ex19del/T790M), with mean IC₅₀ potency less than 15 nM^[1]. In Vivo: The tumor-bearing mice are treated with Osimertinib (AZD-9291) (5 mg/kg/day) for one to two weeks. Within days of treatment, 5 of 5 C/L858R mice displays nearly 80% reduction in tumor volume by magnetic resonance imaging MRI after therapy with Osimertinib (AZD-9291), while 5 of 5 mice treated with vehicle shows tumor growth^[1]. Osimertinib (AZD-9291) demonstrates improved rat PK, reduced hERG affinity, and improved IGF1R margins relative to the previously described compounds, and so this compound is selected for further investigation. Osimertinib (AZD-9291) also offers an additional degree of broader chemical and profile diversity when compared to the previously described lead compounds. Upon dosing Osimertinib (AZD-9291) in three efficacy models, The comparable efficacy is observed at relatively low doses (10 mg/kg per day). The excellent efficacy is also observed when Osimertinib (AZD-9291) is dosed at 5 mg/kg per day^[2].